Federated Hermes, Inc. United Therapeutics Corp Transaction History

Federated Hermes, Inc.

  • $43.6 Billion
  • Q3 2024

A detailed history of Federated Hermes, Inc. transactions in United Therapeutics Corp stock. As of the latest transaction made, Federated Hermes, Inc. holds 6,773 shares of UTHR stock, worth $2.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,773
Previous 6,890 1.7%
Holding current value
$2.5 Million
Previous $2.19 Million 10.62%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$311.04 - $363.55 $36,391 - $42,535
-117 Reduced 1.7%
6,773 $2.43 Million
Q2 2024

Aug 08, 2024
SELL
$228.26 - $319.04 $167,314 - $233,856
-733 Reduced 9.62%
6,890 $2.19 Million
Q1 2024

May 14, 2024
SELL
$210.76 - $249.51 $16,017 - $18,962
-76 Reduced 0.99%
7,623 $1.75 Million
Q4 2023

Jan 31, 2024
SELL
$214.88 - $256.94 $196,830 - $235,357
-916 Reduced 10.63%
7,699 $1.69 Million
Q3 2023

Nov 13, 2023
SELL
$211.82 - $248.24 $77,102 - $90,359
-364 Reduced 4.05%
8,615 $1.95 Million
Q2 2023

Aug 14, 2023
SELL
$205.19 - $232.99 $6,976 - $7,921
-34 Reduced 0.38%
8,979 $1.98 Million
Q1 2023

May 08, 2023
BUY
$212.99 - $276.17 $5,111 - $6,628
24 Added 0.27%
9,013 $2.02 Million
Q4 2022

Feb 13, 2023
SELL
$205.95 - $280.43 $711,351 - $968,605
-3,454 Reduced 27.76%
8,989 $2.5 Million
Q3 2022

Nov 14, 2022
SELL
$203.3 - $244.17 $15,044 - $18,068
-74 Reduced 0.59%
12,443 $2.61 Million
Q2 2022

Aug 15, 2022
SELL
$174.81 - $241.14 $189,843 - $261,878
-1,086 Reduced 7.98%
12,517 $2.95 Million
Q1 2022

May 13, 2022
BUY
$166.16 - $213.96 $10,135 - $13,051
61 Added 0.45%
13,603 $2.44 Million
Q4 2021

Feb 14, 2022
BUY
$184.32 - $216.08 $22,302 - $26,145
121 Added 0.9%
13,542 $2.93 Million
Q3 2021

Nov 15, 2021
BUY
$179.86 - $214.88 $74,102 - $88,530
412 Added 3.17%
13,421 $2.48 Million
Q2 2021

Aug 16, 2021
SELL
$170.47 - $211.93 $1.01 Million - $1.25 Million
-5,909 Reduced 31.23%
13,009 $2.33 Million
Q1 2021

May 13, 2021
SELL
$153.94 - $174.85 $105,294 - $119,597
-684 Reduced 3.49%
18,918 $3.17 Million
Q4 2020

Feb 12, 2021
BUY
$101.87 - $151.79 $15,076 - $22,464
148 Added 0.76%
19,602 $2.98 Million
Q3 2020

Nov 12, 2020
SELL
$99.9 - $121.13 $18,981 - $23,014
-190 Reduced 0.97%
19,454 $1.97 Million
Q2 2020

Aug 13, 2020
BUY
$92.74 - $125.82 $737,561 - $1 Million
7,953 Added 68.03%
19,644 $2.38 Million
Q1 2020

May 13, 2020
SELL
$79.39 - $115.35 $119,005 - $172,909
-1,499 Reduced 11.36%
11,691 $1.11 Million
Q4 2019

Feb 14, 2020
BUY
$78.31 - $95.34 $218,563 - $266,093
2,791 Added 26.84%
13,190 $1.16 Million
Q3 2019

Nov 14, 2019
SELL
$74.85 - $85.99 $18,338 - $21,067
-245 Reduced 2.3%
10,399 $829,000
Q2 2019

Aug 14, 2019
SELL
$76.06 - $120.81 $317,018 - $503,536
-4,168 Reduced 28.14%
10,644 $831,000
Q1 2019

May 10, 2019
BUY
$107.15 - $126.84 $193,191 - $228,692
1,803 Added 13.86%
14,812 $1.74 Million
Q4 2018

Feb 13, 2019
SELL
$101.4 - $128.73 $429,023 - $544,656
-4,231 Reduced 24.54%
13,009 $1.42 Million
Q3 2018

Nov 13, 2018
SELL
$113.81 - $129.46 $70,448 - $80,135
-619 Reduced 3.47%
17,240 $2.21 Million
Q2 2018

Aug 10, 2018
BUY
$101.14 - $118.31 $3,337 - $3,904
33 Added 0.19%
17,859 $2.02 Million
Q1 2018

May 09, 2018
BUY
$107.21 - $151.94 $49,316 - $69,892
460 Added 2.65%
17,826 $2 Million
Q4 2017

Feb 14, 2018
SELL
$118.58 - $151.28 $786,422 - $1 Million
-6,632 Reduced 27.64%
17,366 $0
Q3 2017

Nov 13, 2017
BUY
$114.6 - $136.81 $2.75 Million - $3.28 Million
23,998
23,998 $2.81 Million

Others Institutions Holding UTHR

# of Institutions
672
Shares Held
42.4M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.8B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email